1117 unknown. 1117 Phase 2, 177 Phase 1, 100 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1117 | Unknown 1117 |
| Phase 1 | 177 | Unknown 177 |
| Phase 3 | 100 | Unknown 100 |
Follow Gastrointestinal Diseases: new trials by email Literature Review of Gastrointestinal Diseases trials Research Report on Gastrointestinal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab, CAPOX Chemotherapy - Microsatellite Stable (MSS) Colon Cancer, Locally Advanced Colon Cancer | Phase 2 | Unknown | Sir Run Run Shaw Hospital | 140 | 2024-10-01 | 2024-09-19 |
| BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma BTLA inhibitor (JS004), Toripalimab, Paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Henan Provincial People's Hospital | 20 | 2024-09-30 | 2024-09-19 |
| Exploring Treatments for Children's Abdominal Pain: Comparing Trimebutine and Probiotics Trimebutine, Lactobacillus rhamnosus, Placebo - Functional Abdominal Pain Syndrome, Functional Gastrointestinal Disorders | Phase 1 / Phase 2 | Unknown | Universidad de Colima | 82 | 2024-09-01 | 2024-08-16 |
| Beta-Hydroxybutyrate Feasibility Treating IBD Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's - Crohn's Disease, Inflammatory Bowel Diseases | Phase 1 / Phase 2 | Unknown | University of Texas at Austin | 20 | 2024-08-28 | 2024-09-19 |
| Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study FOLFOXIRI Protocol - Neoplasm Malignant, Colon Cancer Stage 4 | Phase 2 | Unknown | Al-Azhar University | 60 | 2024-08-17 | 2024-08-28 |
| Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer Irinotecan Liposome, Bevacizumab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Unknown | West China Hospital | 20 | 2024-08-09 | 2024-08-09 |
| A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis Sintilimab, Ramucirumab, SOX/XELOX - Stomach Neoplasms | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 39 | 2024-08-01 | 2024-08-28 |
| Prospective Phase II Study on Continuous Circumferential Reinforcement of Laparoscopic Rectal Anastomosis to Prevent Complications Continuous Circumferential Reinforcement of the Anastomotic - Colorectal Cancer, Anastomotic Leakage | Phase 2 | Unknown | ZHI-ZHONG PAN | 208 | 2024-07-20 | 2024-07-11 |
| MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer PD-1 monoclonal antibody consolidation therapy - Esophageal Cancer | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 102 | 2024-07-16 | 2024-08-06 |
| Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC. Adebrelimab, Apatinib, Investigator chosen chemotherapy (ICC) - Esophageal Cancer | Phase 2 | Unknown | The First Affiliated Hospital of Henan University of Science and Technology | 54 | 2024-07-15 | 2024-06-18 |
| Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer Trilaciclib Injection [Cosela], Placebo - Esophageal Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2024-07-09 | 2024-08-26 |
| First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer mfolfox6 and hlx04 regimen and Serplulimab, mfolfox6 and hlx04 regimen - Efficacy, Self, Safety Issues | Phase 2 | Unknown | Sir Run Run Shaw Hospital | 72 | 2024-07-01 | 2024-07-09 |
| Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer Liposomal irinotecan, Bevacizumab - Colorectal Cancer | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 74 | 2024-06-05 | 2024-05-30 |
| Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis CU104, Placebo - Ulcerative Colitis | Phase 2 | Unknown | Curacle Co., Ltd. | 45 | 2024-06-01 | 2023-06-18 |
| Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation - Gastric Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 138 | 2024-06-01 | 2024-05-17 |
| Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody - Metastatic Colorectal Cancer, MSS | Phase 2 | Unknown | Zhangfa Song | 36 | 2024-06-01 | 2024-05-16 |
| Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer Liposomal Irinotecan Hydrochloride - Gastric Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 50 | 2024-05-27 | 2024-05-31 |
| Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer Adebrelimab combined with DOS - Gastric Cancer | Phase 2 | Unknown | Tang-Du Hospital | 42 | 2024-05-24 | 2024-06-26 |
| Multimodal Imaging in Rectal Cancer & Pancreatic Cancer [111In]In-DOTA-ANTI-CEA antibody injection, SPECT/CT scan, Resection surgery - Rectal Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Unknown | Radboud University Medical Center | 20 | 2024-05-02 | 2024-05-02 |
| A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer SC0191, SC0191 + Bevacizumab, SC0191 + 5-FU/LV - Metastatic Colorectal Cancer | Phase 2 | Unknown | Tianshu Liu | 36 | 2024-05-01 | 2024-04-12 |
Showing 20 of 1117. Sign in to see all of them.
Colorectal Neoplasms (324) · Stomach Neoplasms (285) · Rectal Neoplasms (123) · Esophageal Neoplasms (121) · Esophageal Squamous Cell Carcinoma (102) · Colonic Neoplasms (90) · Neoplasm Metastasis (34) · Colitis, Ulcerative (33) · Pancreatic Neoplasms (29) · Neoplasms (27) · Breast Neoplasms (23) · Crohn Disease (23) · Gastrointestinal Neoplasms (21) · Inflammatory Bowel Diseases (20) · Carcinoma, Non-Small-Cell Lung (17)
Digestive System Diseases (1112) · Neoplasms by Site (941) · Digestive System Neoplasms (937) · Neoplasms (934) · Gastrointestinal Neoplasms (922) · Intestinal Diseases (589) · Intestinal Neoplasms (475) · Colonic Diseases (438) · Rectal Diseases (438) · Stomach Diseases (301) · Esophageal Diseases (225) · Head and Neck Neoplasms (207) · Neoplasms by Histologic Type (166) · Colorectal Neoplasms (156)
Oxaliplatin (127) · Capecitabine (107) · Fluorouracil (84) · Irinotecan (76) · Paclitaxel (60) · Cisplatin (56) · S 1 (combination) (55) · Bevacizumab (53) · Leucovorin (51) · Cetuximab (48) · apatinib (44) · Radiotherapy (43) · Drug Therapy (40) · sintilimab (40) · camrelizumab (38)
Fudan University (44) · Sun Yat-sen University (36) · Chinese Academy of Medical Sciences (25) · Tianjin Medical University Cancer Institute and Hospital (23) · Peking University (17) · Zhejiang Cancer Hospital (17) · National Cancer Center, Korea (16) · The First Affiliated Hospital of Zhengzhou University (14) · The First Affiliated Hospital with Nanjing Medical University (14) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (13) · Fujian Cancer Hospital (13) · Shanghai Zhongshan Hospital (13) · National Taiwan University Hospital (11) · Second Affiliated Hospital, Zhejiang University, School of Medicine (11) · Chinese PLA General Hospital (10)
China (524) · United States (81) · South Korea (69) · Netherlands (30) · France (28) · Taiwan (26) · United Kingdom (26) · Italy (25) · Japan (25) · Canada (21) · Germany (21) · Israel (19) · Spain (19) · Brazil (14) · Denmark (14)
Feng Wang (5) · Lin Shen, MD (5) · Wei Peng Yong, MRCP, MB ChB (5) · Cathy Hammerman, MD (3) · Fuxiang Zhou, M.D. (3) · Jingdong Zhang (3) · Lin Shen, Professor (3) · Ruihua Xu, MD, PhD (3) · Se Hoon Park, MD (3) · Shixiu Wu, MD (3) · Yanhong Gu (3) · Zhen Zhang, MD (3) · Akira Tsuburaya (2) · Anwaar Saeed, MD (2) · Changming Huang, Professor (2)
PMID 35623069, PMID 15273542, PMID 25447852, PMID 25514302, PMID 26313683, PMID 26755520, PMID 26884585, PMID 27480145, PMID 30348638, PMID 30642373, PMID 32306237, PMID 34725214, PMID 35219300, PMID 36657089, PMID 38421211, PMID 41379261, PMID 9146781, PMID 10089184, PMID 10091726, PMID 10400410, PMID 10744089, PMID 11091234, PMID 11223832, PMID 11231246, PMID 11239312, PMID 11247898, PMID 11248153, PMID 11289756, PMID 11413430, PMID 11491192, PMID 11712875, PMID 11754382, PMID 11813623, PMID 11914441, PMID 12187070, PMID 12196368, PMID 12378346, PMID 12510709, PMID 12756590, PMID 1334988, PMID 14578723, PMID 14759776, PMID 14967459, PMID 15083176, PMID 15131807, PMID 15175435, PMID 15496622, PMID 15668283, PMID 15711856, PMID 15783049
2018 (5), P30CA015083 (4), 2008 (3), 2015 (3), 2016 (3), 2005 (2), 2009 (2), 2014 (2), 2019 (2), 2023 (2), 2017 (1), K08HD052885 (1), P30CA168524 (1), R01NR010730 (1), U10CA031946 (1)